Actinium Pharmaceuticals, Inc. (ATNM) Stock Price & Analysis
Actinium Pharmaceuticals, Inc. (ATNM) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $1.08 (-20.00%), as of the Nov 18, 2026 trading session; market cap $34.0M.
Educational signal · not a buy or sell recommendation · How to read this
Actinium Pharmaceuticals, Inc. · ATNM · AMEX
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Actinium Pharmaceuticals (ATNM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, at a cheap price. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $35M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 5 of the last 8 reports
- Altman Z -8.30 · Piotroski F 4
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.08 | |
| Change on the day | -20.00% | |
| 52-week range | $0.735 – $1.72 | |
| Market capitalisation | $34.0M | — |
| Price / earnings (trailing) | 3.75 | |
| Shares traded on the day | 326.8K |
Price & events
Other perspectives
Council score for Actinium Pharmaceuticals (ATNM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 14, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Actinium Pharmaceuticals (ATNM), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Actinium Pharmaceuticals, Inc. (ATNM) is listed on AMEX. It employs 27 people and is led by Sandesh C. Seth. In Q2 FY2026 it reported revenue of $35M and net income of $28M. The market values it at $34.0M.
What do the latest results show for Actinium Pharmaceuticals (ATNM)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $35M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $35M | $28M | $0.89 (diluted) |
| Q3 FY2025 | $90,000 | -$5M | -$0.16 (diluted) |
What are the financial strengths and risks for Actinium Pharmaceuticals (ATNM)?
Short answer · as of
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z -8.30 · Piotroski F 4. Trailing ratios: ROE 83.4% · ROA 28.2% · current ratio 4.08 · earnings yield 22.0% · free-cash-flow yield -45.1%.
How does Actinium Pharmaceuticals compare with its peers?
Short answer
Actinium Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Actinium Pharmaceuticals (ATNM) — this page | $1.08 | $34.0M | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ATNM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ATNM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Actinium Pharmaceuticals (ATNM)?
Common Questions About ATNM
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ATNM?
ATNM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ATNM a good stock to buy?
Stock Expert AI does not rate ATNM buy, sell or hold. Actinium Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ATNM stock price today?
The last price recorded for Actinium Pharmaceuticals, Inc. (ATNM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ATNM?
Actinium Pharmaceuticals, Inc. (ATNM) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Collaborations with Astellas Pharma, Inc., EpicentRx, Inc., and AVEO Oncology to expand therapeutic applications. Not financial advice.
How frequently does ATNM data refresh on this page?
ATNM's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ATNM's recent stock price performance?
Actinium Pharmaceuticals, Inc. (ATNM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology in targeted radiotherapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATNM overvalued or undervalued right now?
The trailing P/E of Actinium Pharmaceuticals, Inc. (ATNM) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ATNM before investing?
Before investing in Actinium Pharmaceuticals, Inc. (ATNM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ATNM to a portfolio?
Key strength of Actinium Pharmaceuticals, Inc. (ATNM): Proprietary technology in targeted radiotherapy. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com